Branded Legacy Advances Engineering of Air-Driven Intranasal Drug Delivery Mold

Branded Legacy, Inc. (OTC: BLEG) has announced that its subsidiary, BioLegacy Evaluative Group Inc., has initiated engineering and development of a unitary device mold for its proprietary air-driven intranasal drug delivery platform. This significant milestone represents a crucial step toward scalable production of the company's single-use device designed for rapid and reliable therapeutic delivery. The development particularly advances the company's flagship inhaled naloxone program, positioning the technology as a potential game-changer in opioid overdose response and addiction treatment.

The engineering progress builds upon the company's September 2025 provisional patent filing and the recent opening of a GMP-compliant facility in Vancouver. This strategic advancement strengthens Branded Legacy's capacity to address the ongoing opioid crisis through affordable, high-quality pharmaceutical solutions. The air-driven intranasal delivery platform represents an innovative approach to medication administration, potentially offering faster absorption and improved bioavailability compared to traditional delivery methods.

The development of the unitary device mold is critical for mass production capabilities, enabling the company to potentially scale manufacturing to meet public health demands. This engineering phase focuses on creating a mold that can produce consistent, reliable devices for the intranasal delivery system. The technology's design aims to provide rapid therapeutic effects, which is particularly crucial for emergency situations such as opioid overdose reversal where seconds can mean the difference between life and death.

Branded Legacy's progress in engineering the delivery device mold represents a significant step forward in the company's mission to provide innovative solutions in the addiction treatment and harm reduction space. The company maintains its commitment to advancing pharmaceutical technologies that can make a meaningful impact on public health challenges. For additional information about the company's initiatives, visit https://BrandedLegacy.com. The full press release detailing this development can be accessed at https://ibn.fm/Lgrhz.